Cytek Narrows 2026 Revenue Outlook and Delays Business-Unit Rollout
Photo: TokenPost
Cytek Biosciences narrowed its 2026 revenue outlook and postponed a planned business-unit rollout until 2027, keeping its forecast midpoint at $209.5 million as third-quarter revenue rose 2% year over year. The company now expects full-year revenue of $208 million to $211 million for the year ending Dec. 31. Its previous forecast was $207 million to $212 million. The revised range trims $1 million from each end while preserving the same midpoint. The outlook assumes current foreign currency exchange rates do not change. Revenue for the three months ended Sept.
Source: TokenPost
